Brought to you by 
GSK licenses rights to OTC version of cold sore candidate
11 May 2011
Executive Summary
GlaxoSmithKline Consumer Healthcare has received exclusive US and Canadian rights to an over-the-counter version of NB001 (also known as NanoHPX), which is being developed by NanoBio (nanoemulsion drug formulations) for cold sores.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- OTC, Consumer
-
Biotechnology
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK licenses rights to OTC version of cold sore candidate
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice